| Literature DB >> 33457271 |
Luck Hee Sung1, Hyeong Dong Yuk2.
Abstract
Radical cystectomy (RC) is the standard treatment for patients diagnosed with muscle invasive bladder cancer, but is associated with significant morbidity and long hospital stays. Enhanced recovery after surgery (ERAS) is based on a variety of interventions during the peri-treatment stage. It is designed to improve morbidity, enhance recovery, and reduce hospital stays after RC. The study provides an overview of the key elements of the ERAS protocol recommended for patients undergoing RC and directions for further research. We have analyzed the rationale for 15 key elements related to the ERAS protocol: preoperative patient counseling and education, preoperative medical optimization and nutrition, mechanical bowel preparation, preoperative fasting and carbohydrate loading, pre-anesthetic medication, thromboembolic prophylaxis, minimally invasive surgical approach, resection-site drainage, preventing intraoperative hypothermia, perioperative fluid management, perioperative analgesia, urinary drainage, prevention of postoperative ileus, nausea and vomiting, early oral feeding, and early mobilization. Several studies have shown that ERAS improves the recovery of RC patients. Evidence suggests that ERAS facilitates the recovery of RC patients. However, additional randomized controlled studies or large prospective studies are needed to demonstrate the effectiveness of ERAS in RC patients. 2020 Translational Andrology and Urology. All rights reserved.Entities:
Keywords: Bladder cancer; enhanced recovery after surgery (ERAS); perioperative care; radical cystectomy (RC)
Year: 2020 PMID: 33457271 PMCID: PMC7807364 DOI: 10.21037/tau.2020.03.44
Source DB: PubMed Journal: Transl Androl Urol ISSN: 2223-4683
Summary of preoperative, intraoperative, and postoperative ERAS items
| ERAS items | Summary |
|---|---|
| Preoperative items | |
| Patient counseling and education | Stoma/neobladder care; alcohol consumption cessation of smoking |
| Medical optimization | – |
| Nutrition optimization | – |
| No mechanical bowel preparation | – |
| Carbohydrate loading | Solids up to 6 hours before surgery |
| Clear fluids up to 2 hours before surgery | |
| Intraoperative items | |
| Thromboembolic prophylaxis | Compression stockings; low-molecular-weight heparin |
| Minimal invasive surgery | – |
| Standard anesthetic protocol | – |
| Fluid management | Goal-directed fluid therapy using esophageal Doppler |
| Preventing hypothermia | – |
| Ureteral stent indwelling in ureteroileal anastomosis | Promoting intestinal recovery; reducing metabolic acidosis |
| Postoperative items | |
| Removal of nasogastric tube | – |
| Prevention of nausea and vomiting | Goal-directed fluid therapy during surgery |
| Prokinetic agents, antiemetics, dexamethasone, and propofol use | |
| Indwelling ureteral stent in ureteroileal anastomosis | |
| Prevention of ileus | Chewing gum; oral laxatives; alvimopan; RARC > open RC |
| Resection-site drainage | Remove on the postoperative day 1 if there is no evidence of urine leakage |
| Analgesia | Thoracic epidural analgesia up to 48 or 72 hours |
| Minimal opioids and short-acting opioids based on fentanyl | |
| Regular administration of nonsteroidal anti-inflammatory drugs, acetaminophen | |
| Urinary drainage | Transurethral catheters should be removed on postoperative one day |
| Remove the ureteral stent within 2 weeks after surgery | |
| Early oral feeding | – |
| Early mobilization | – |
ERAS, enhanced recovery after surgery; RARC, robot-assisted radical cystectomy.
Studies evaluating the role of ERAS in radical cystectomy
| Study | Year | Patients | Design | Operation type | Intervention group | Outcomes |
|---|---|---|---|---|---|---|
| Tamhankar | 2020 | 35 | Retrospective | RARC + IUD | ERAS | Median LOS: 8 [4–30] days |
| Overall complication 45.7%, ≥ grade 3 complication 14.3% | ||||||
| 90-day mortality: 0% | ||||||
| Ghoreifi | 2020 | 427 | Retrospective | RC | ERAS | 90-day UTI: 36.1%, 90-day sepsis: 7.1% |
| Ziegelmueller | 2019 | 35 | Prospective, randomization | RC | ERAS/conservative regimen | ERAS |
| Kotov | 2019 | 134 | Prospective | RC + LRC | ERAS | 90-day complication: 70%, ≥ grade 3 complication: 32%, 90-day mortality: 11.9%, LOS: 12 [9–16] days |
| Dunkman | 2019 | 200 | Retrospective | RC | Traditional care/ERAS | Median LOS:10 [8–18] |
| Days to first stool: 5.83 | ||||||
| Days to first solid food: 9.68 | ||||||
| Cheng | 2019 | 512 | Retrospective | RC | ERAS | ICU admission: 6.4%, median ICU day: 3 [0–32] days |
| Median LOS: 11.5 days (ICU), 5 days (non-ICU) | ||||||
| Zainfeld | 2018 | 289 | Retrospective | RC | ERAS | Median LOS: 4 days, 30-day complication and readmission: 58.8% and 16.6% |
| Tan | 2018 | 304 | Prospective | ORC + RARC + IUD | ORC/RARC/RARC with ERAS | Median LOS: 17 [14–21] days/11 [8–15] days/7 [6–10] days |
| 90-day complication and readmission is lower in RARC with EARS group | ||||||
| Semerjian | 2018 | 110 | Retrospective | RC | Pre-ERAS/post-ERAS | Median LOS: 8.5 |
| Overall complication, 90-day readmission: no difference | ||||||
| Patel | 2018 | 259 | Retrospective | RC | Pre-ERAS/post-ERAS | LOS, 90-day complication and readmission: no difference |
| Pang | 2018 | 446 | Retrospective | RC | ERAS/ without ERAS | LOS: 8 [6–13] |
| Readmission: 15% | ||||||
| Palumbo | 2018 | 114 | Retrospective | ORC | ERAS/standard preoperative care | 3-day passage of stool: 50% |
| 90-day complication 22.5% | ||||||
| Matulewicz | 2018 | 171 | Retrospective | RC | Pre-ERAS/post-ERAS | Median LOS: 8.5 |
| Liu | 2018 | 260 | Retrospective | RC | Pre-ERAS/post-ERAS | Mean LOS: 14.25 |
| Kukreja | 2018 | 383 | Prospective | RC | ERAS/traditional care | Reduced immediate postoperative symptom: pain, drowsiness, dry mouth, disturbed sleep, interference with functioning |
| Frees | 2018 | 27 | Prospective, randomization | RC | ERAS/standard protocol | LOS: 6.1 [5–7] |
| Time to flatulence 2.5 [2–4] | ||||||
| Time to defecation 4.3 [2–6] | ||||||
| Bazargani | 2018 | 180 | Retrospective | RC | ERAS | Median LOS: 4 days, 30- and 90-day complication: 59% and 75% |
| Bazargani | 2018 | 292 | Retrospective | RC | Pre-ERAS/post-ERAS | Median time to first flatus: 2 days, median LOS: 4 days |
| 30-day GI complication: 27% | ||||||
| Djaladat | 2017 | 169 | Retrospective | RC | ERAS | 90-day major and minor complication: 24.3% and 53.9% |
| 90-day readmission: 29.6% | ||||||
| Baack | 2017 | 200 | Retrospective | RC | Pre-ERAS/post-ERAS | Median LOS: 8 |
| 90-day complication and readmission: no difference | ||||||
| Collins | 2016 | 135 | Retrospective | RC | Pre-ERAS/post-ERAS | Median LOS: 9 [8–13] |
| 30-day complication, readmission and 90-day mortality: no difference | ||||||
| Xu | 2015 | 205 | Retrospective | RC | ERAS/Traditional care | Opioid per day: 4.9 |
GI, gastrointestinal; IUD, intracorporeal urinary diversion; IVLI, intravenous lidocaine infusion; LOS, length of hospital day; LRC, laparoscopic radical cystectomy; ORC, open radical cystectomy; RARC, robot-assisted radical cystectomy; RC, radical cystectomy; VTE, venous thromboembolism.